Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Diabetes Care · 2009 · PMC2646035 · PMID 18984774

Europe PMC DOI

hedged sentence

0.0050

closest p · 0.1× alpha

0.0050

boldest claim

The sentences

borderline significanceP = 0.005actually significant

Indeed, the overall effect of fenofibrate in the presence of marked dyslipidemia was larger than that in all other groups, with borderline significance of treatment by group interaction: marked dyslipidemia group: 27% risk reduction (adjusted HR 0.73 [95% CI 0.58–0.91], P = 0.005); all others: 6% risk reduction (0.94 [0.83–1.06], P = 0.321; P interaction = 0.053) ( Fig. 2 ).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.